{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=25",
    "query": {
      "intervention": "Active capsule",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 1413,
    "total_pages": 142,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T07:18:52.574Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06628908",
      "title": "Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Peripheral Neuropathic Pain"
      ],
      "interventions": [
        {
          "name": "Suzetrigine",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to SUZ)",
          "type": "DRUG"
        },
        {
          "name": "Pregabalin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to Pregabalin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1100,
      "start_date": "2024-10-01",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-26T07:18:52.574Z",
      "location_count": 76,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06628908"
    },
    {
      "nct_id": "NCT03566290",
      "title": "Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stress Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "GTx-024",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GTx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2018-06-28",
      "completion_date": "2018-09-21",
      "has_results": false,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-10-26T07:18:52.574Z",
      "location_count": 46,
      "location_summary": "Homewood, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03566290"
    },
    {
      "nct_id": "NCT04895410",
      "title": "Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Lemzoparlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2022-01-17",
      "completion_date": "2022-06-24",
      "has_results": false,
      "last_update_posted_date": "2023-03-06",
      "last_synced_at": "2026-10-26T07:18:52.574Z",
      "location_count": 12,
      "location_summary": "Miami, Florida • Tampa, Florida • Louisville, Kentucky + 9 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895410"
    },
    {
      "nct_id": "NCT00415142",
      "title": "An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "saredutant (SR48968)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "escitalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "60 Years to 64 Years"
      },
      "enrollment_count": 393,
      "start_date": "2006-12",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2016-05-24",
      "last_synced_at": "2026-10-26T07:18:52.574Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00415142"
    },
    {
      "nct_id": "NCT02178696",
      "title": "Predictors of Antidepressant Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Placebo, identified as placebo to participants",
          "type": "OTHER"
        },
        {
          "name": "Celexa or other antidepressant as clinically indicated",
          "type": "DRUG"
        },
        {
          "name": "Placebo, identifed to participants as \"Active medication\"",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 44,
      "start_date": "2011-01",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-10-26T07:18:52.574Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178696"
    },
    {
      "nct_id": "NCT04283097",
      "title": "Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematological Malignancies"
      ],
      "interventions": [
        {
          "name": "KPG-818",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kangpu Biopharmaceuticals, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-09-13",
      "completion_date": "2024-12-12",
      "has_results": false,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-26T07:18:52.574Z",
      "location_count": 10,
      "location_summary": "Sacramento, California • Plantation, Florida • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04283097"
    },
    {
      "nct_id": "NCT00705003",
      "title": "Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD",
          "type": "DRUG"
        },
        {
          "name": "BCI-024 (Buspirone)",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 142,
      "start_date": "2008-05",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2014-06-18",
      "last_synced_at": "2026-10-26T07:18:52.574Z",
      "location_count": 9,
      "location_summary": "Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Altanta",
          "state": "Georgia"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Beachwood",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00705003"
    },
    {
      "nct_id": "NCT04142762",
      "title": "A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "ABI-H2158",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Ethinyl Estradiol / Levonorgestrel",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching oral contraceptive",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Assembly Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2019-10-18",
      "completion_date": "2020-01-29",
      "has_results": false,
      "last_update_posted_date": "2020-03-04",
      "last_synced_at": "2026-10-26T07:18:52.574Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04142762"
    },
    {
      "nct_id": "NCT01094262",
      "title": "A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis",
        "Osteoarthritis, Knee",
        "Pain",
        "Arthralgia",
        "Joint Pain"
      ],
      "interventions": [
        {
          "name": "Oxycodone CR (standard pain medication)",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42160443",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 196,
      "start_date": "2010-04-20",
      "completion_date": "2011-07-01",
      "has_results": false,
      "last_update_posted_date": "2020-03-11",
      "last_synced_at": "2026-10-26T07:18:52.574Z",
      "location_count": 36,
      "location_summary": "Tucson, Arizona • Carmichael, California • Pismo Beach, California + 33 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Pismo Beach",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01094262"
    },
    {
      "nct_id": "NCT01279590",
      "title": "Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myalgia",
        "Hypercholesterolemia",
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "PPD10558",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Furiex Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 282,
      "start_date": "2011-03",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2011-12-22",
      "last_synced_at": "2026-10-26T07:18:52.574Z",
      "location_count": 67,
      "location_summary": "Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01279590"
    }
  ]
}